Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat before pulmonary endarterectomy in operable CTEPH with high preoperative pulmonary vascular resistance
2017-001121-40Phase 2Terminated
- Sponsor
- International CTEPH Association
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Riociguat with Placebo (2 arms). Primary endpoint: Percent change from baseline in pulmonary vascular resistance immediately before pulmonary endarterectomy. Started Feb 2018; status: terminated.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2017-001121-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001121-40.